Gilead Sciences, Inc. $GILD Holdings Lifted by Leuthold Group LLC

Leuthold Group LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,247 shares of the biopharmaceutical company’s stock after purchasing an additional 5,216 shares during the period. Leuthold Group LLC’s holdings in Gilead Sciences were worth $8,682,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Client 1ST Advisory Group LLC grew its stake in shares of Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 69 shares in the last quarter. Bfsg LLC raised its stake in Gilead Sciences by 7.7% in the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 72 shares in the last quarter. Grove Bank & Trust raised its stake in Gilead Sciences by 1.2% in the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 74 shares in the last quarter. Wilkerson Advisory Group LLC lifted its holdings in Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 78 shares during the last quarter. Finally, HBW Advisory Services LLC lifted its holdings in Gilead Sciences by 2.4% during the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock worth $473,000 after buying an additional 79 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 102,619 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the sale, the chief executive officer owned 551,683 shares in the company, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 242,709 shares of company stock valued at $39,503,427 over the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $169.32 on Tuesday. The company has a fifty day moving average of $153.51 and a two-hundred day moving average of $141.14. The company has a market capitalization of $210.01 billion, a PE ratio of -53.58 and a beta of 0.35. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the firm earned $2.47 earnings per share. The business’s revenue was up 6.8% compared to the same quarter last year. As a group, analysts expect that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on GILD shares. Scotiabank increased their price objective on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Royal Bank Of Canada upped their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a report on Friday, October 30th. UBS Group increased their price target on shares of Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.